Madrigal PharmaceuticalsMDGL
MDGL
About: Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
Employees: 376
0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
29% more call options, than puts
Call options by funds: $216M | Put options by funds: $168M
2% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 44
1% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 82
1% less funds holding
Funds holding: 255 [Q2] → 253 (-2) [Q3]
4.17% less ownership
Funds ownership: 108.59% [Q2] → 104.42% (-4.17%) [Q3]
26% less capital invested
Capital invested by funds: $6.48B [Q2] → $4.77B (-$1.71B) [Q3]
36% less funds holding in top 10
Funds holding in top 10: 14 [Q2] → 9 (-5) [Q3]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$236
28%
downside
Avg. target
$376
15%
upside
High target
$441
34%
upside
4 analyst ratings
3 positive
75%
1 neutral
25%
0 negative
0%
HC Wainwright & Co. Ed Arce 44% 1-year accuracy 72 / 162 met price target | 22%upside $400 | Buy Maintained | 14 Jan 2025 |
JMP Securities Jonathan Wolleben 38% 1-year accuracy 27 / 72 met price target | 30%upside $427 | Market Outperform Reiterated | 10 Jan 2025 |
B. Riley Securities Mayank Mamtani 30% 1-year accuracy 7 / 23 met price target | 28%downside $236 | Neutral Maintained | 5 Nov 2024 |
UBS Eliana Merle 21% 1-year accuracy 4 / 19 met price target | 34%upside $441 | Buy Maintained | 1 Nov 2024 |
Financial journalist opinion
Based on 8 articles about MDGL published over the past 30 days
Positive
Seeking Alpha
1 week ago
Madrigal Pharmaceuticals Rezdiffra Vies For Blockbuster Status In MASH
Madrigal Pharma's REZDIFFRA achieved $100-$103M in Q4 sales, marking 61% growth, with market penetration of only 4% relative to TAM, indicating blockbuster potential. Potential competition from GLP-1 drugs and other MASH therapies exists, but REZDIFFRA's combination use and first-mover advantage mitigate these risks. Analysts project $515M in 2025 sales, driven by Medicare coverage, low market penetration, and European launch, making MDGL stock a STRONG BUY.
Negative
The Motley Fool
1 week ago
Why Madrigal Pharmaceuticals Stock Was Plummeting This Week
An estimates-beating set of preliminary financial numbers and two bullish analyst updates weren't enough to lift Madrigal Pharmaceuticals (MDGL -0.59%) stock out of the doldrums over the past few trading days. Investor expectations are clearly very high, as the company's share price had withered by nearly 20% week to date as of Friday before market open, according to data compiled by S&P Global Market Intelligence.
Negative
Zacks Investment Research
1 week ago
MDGL Stock Down 10% on Disappointing Preliminary Q4 Rezdiffra Sales
Madrigal stock slides 10% as the preliminary Q4 Rezdiffra sales figures failed to impress investors.
Negative
The Motley Fool
1 week ago
Why Madrigal Pharmaceuticals Stock Is Sinking Today
Shares of Madrigal Pharmaceuticals (MDGL -13.81%) were sinking 13.3% lower as of 11:11 a.m. ET on Monday.
Neutral
GlobeNewsWire
1 week ago
Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra
CONSHOHOCKEN, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced an update on its business performance, including preliminary* fourth-quarter and year-end net sales, year-end cash and patients on Rezdiffra.
Positive
Seeking Alpha
2 weeks ago
Fast Drug Launch For Madrigal Pharmaceuticals Brings Buyout Discussion
Rezdiffra's strong launch has been confirmed by robust sales in the first two quarters, even though it may have only been used in 2% of its current target patient population. Competitors with MASH therapies like NVO, SGMT, ALT and Boehringer Ingelheim are making progress, although the possibility of combinations could limit any downside for MDGL. There is ongoing discussion about a potential buyout, adding another layer of interest for investors, and a potential EU launch in H2'25.
Positive
CNBC
2 weeks ago
Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market
The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will take Accolade private.
Neutral
GlobeNewsWire
3 weeks ago
Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CONSHOHOCKEN, Pa., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 2:15 pm PT. The presentation will be webcast live and can be accessed here or by visiting Madrigal's Investor Relations Site, Events and Presentations.
Negative
Benzinga
2 months ago
Top 3 Health Care Stocks That May Dip This Month
As of Nov. 25, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Positive
The Motley Fool
2 months ago
3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move
When a company's shares shoot up 82% in 12 months, investors clearly think it's a good time to be a shareholder -- and that's exactly what's happened to the stock of Madrigal Pharmaceuticals (MDGL 5.53%). Earlier this year, the up-and-coming biotech received approval of a pioneering liver-disease treatment.
Charts implemented using Lightweight Charts™